The effects of diaspirin-crosslinked hemoglobin on the assessment of immunohematology profiles.

BACKGROUND: Extensive studies have been conducted on the in vitro effects of diaspirin-crosslinked hemoglobin (DCLHb) in biochemical, hematologic, hemostatic, and blood banking (immunohematologic) methods. The absence of red cell antigens or plasma and/or serum antibodies allows DCLHb to be used as "universal-donor" material. This study evaluates the effects of DCLHb on the accurate assessment of the immunohematologic profile (ABO and Rh blood grouping, antibody screen, and crossmatching). STUDY DESIGN AND METHODS: DCLHb, 7.4 g per dL in an electrolyte solution, was mixed in vitro with human whole blood, representing the blood types A Rh-positive. A Rh-negative, B Rh-positive, B Rh-negative, O Rh-positive, O Rh-negative, and AB Rh-positive. Two concentrations of DCLHb were tested: 10-percent (0.74 g/dL) and 30-percent (2.22 g/dL). Controls were prepared by adding a 5-percent albumin solution to aliquots of whole blood in volumes equivalent to those used in preparing the DCLHb dilutions. Serum and/or red cell suspensions from these admixed samples were analyzed for their ABO and Rh blood groups, the presence of unexpected antibodies (antibody screen), and compatibility in crossmatch testing. RESULTS: DCLHb added to whole blood in vitro had no effect on the accurate interpretation of the immunohematologic profile. CONCLUSION: DCLHb does not appear to inhibit the true response or crossreact in the analysis of blood grouping, antibody screening, or crossmatching. In addition, the red color of DCLHb (up to 2.22 g/dL) did not obscure the visual reading for agglutination.

A flow cytometric method for counting very low levels of white cells in blood and blood components.

Reduction of white cells (WBCs) in blood components may reduce the risk of virus transmission and HLA alloimmunization. Filtration provides a means by which to achieve high-efficiency WBC reduction. A method has been developed using flow cytometry to quantitate the number of WBCs in WBC-reduced packed red cells or platelet concentrates. This method uses a detergent and propidium iodide (PI) solution to label the WBC nuclei and incorporates a known amount of fluorescein isothiocyanate (FITC)-labeled chicken red cells (cRBCs) into the mixture as an indicator of the volume examined. The number of observed WBCs per mL is calculated as follows: Number of PI WBC nuclei events/Number of FITC cRBC events x Number of FITC cRBCs added to mixture/Volume of blood in mixture. The method may allow the detection of WBCs at a concentration as low as 0.01 per microliters (10/mL) in a blood sample. It is an efficient method of collecting data, as it requires less than 10 minutes per sample. This flow cytometric technique is suitable for research purposes and for quality control of WBC-reduced blood components, because it is precise and can be used to quantitate WBCs in large or small numbers in a sample.